To provide a quantitative description of the treatments applied to malignant colorectal cancer across Europe, we analysed all cases (11333) of colorectal cancer registered in 1987 by 15 Cancer Registries in eight European countries. In a third of cancer registries, therapy was known for all cases, in the others l-15% of registrations lacked treatment information. Eighty per cent of all patients received surgical resection, ranging from 58% (Estonia) to 92% (Tarn). The proportion of resections decreased with advancing age (85-73% for colon cancer; 85-70% for rectal cancer for <65 years to >74 years, respectively). Only 4% of colon cancer patients received adjuvant or palliative chemotherapy, range l-12%. Sixteen per cent of rectal cancer patients received radiotherapy with great inter-registry variability (l-43%). Since the proportion of surgically resected patients correlated positively with the 5-year relative survival probability reported by the recently published EUROCARE study, this may be part of the explanation for the major differences in survival for these cancers among different European populations. The most likely determinant of this correlation is stage at diagnosis, but, quality of, and access to surgery, as well as access to endoscopy, may differ among countries and registry areas, and these may also contribute to inter-country survival differences. Copyright 0 1996 Elsevier Science Ltd
INTRODUCTION
BASED ON combined data collected by 30 population-based cancer registries for cases diagnosed during [1978] [1979] [1980] [1981] [1982] [1983] [1984] [1985] and analysed by EUROCARE, the 5year relative survival for colorectal cancer patients in Europe was approximately 40%
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PATIENTS AND METHODS
The study analysed all the colorectal (ICD-9 153,154) [2] cancers occurring in 1987 in 15 European populations, for whom relatively complete data on treatment were available, covered by cancer registries in eight countries. Only malignant invasive turnours, as defined by ICD-0 behaviour code 3 or higher [3] were considered; in situ, uncertain and borderline tumours were excluded, as were carcinoids and non-epithelial tumours. Both microscopically verified and non-verified cases were included, but cases known to registries by death certificate only (DCO) or discovered incidentally at autopsy, were excluded. Table 1 shows a breakdown of the total 11 333 colorectal cancer cases according to participating cancer registry and country. The registries of Finland and Estonia cover the entire populations of those countries. France, The Netherlands, Switzerland and the U.K. are represented by two or more registries. Italy and Poland are represented by single registries covering small areas. Most of the cases were from registries in Northern Europe and almost 50% were from the two U.K. registries. Table 1 also provides information on the distribution by sex, age and cancer site according to registry. The proportion of males ranged from 44% (Finland) to 59% (Cote d'Or). 43% of cases were over 74 years of age, varying between 28% (Estonia and Cracow) and 46% (Geneva and Basel). The number of colon cancer cases was usually slightly higher than that of rectal cancer. The proportion of cases confirmed either histologically or cytologically ("microscopically verified") generally ranged between 80% (Mersey) and 99% (Base1 and Eindhoven), but in Cracow only 45% of cases were "microscopically" confirmed.
The major sources of information for most cancer registries are medical records and pathology files and sometimes death certificates, to collect a minima1 set of information for routine cancer incidence studies. Cancer registries were asked to provide information on whether patients underwent surgical resection and/or radiotherapy, chemotherapy or other treatment. If surgical resection, radiotherapy, chemotherapy or other treatment was mentioned in the registry file, it was entered as such; if none were mentioned, the item was entered as "therapy not known". Detailed information on type of surgery, or radiotherapeutic or chemotherapeutic regimen adopted was not requested. However, to provide as complete a picture as possible on therapy, the participating registries were asked to re-check the clinical records of patients for whom no information on treatment had been recorded. Two large registries (Finland and Thames) did not perform this check.
Surgical resection was defined as any surgical intervention which removed the tumour, whether with radical or palliative intent. When only by-pass surgery was performed, it was classified as "other treatment", although the Finnish cancer registry could not separate by-pass surgery from resection as defined above.
Because the age-distributions of patients differed between registries, the proportions of patients given particular types of treatment were age-adjusted using the direct method, i.e. the proportion of cases treated in each IO-year age group (<35, 35-44, 45-54, 55-64, 65-74, 75+) for each registry was applied to the age distribution of the total series of cases. The age-stratified homogeneity test was used for testing treatment differences between cancer registries or between countries [4]. Table 2 shows the (age-adjusted) percentages of colorectal cancer patients who received surgical resection either alone or in association with chemotherapy or radiotherapy, and the percentages of patients given "other treatments" (symptomatic or palliative, including chemotherapy, radiotherapy and by-pass surgery). In 8% of cases, there was no information on therapy. Overall, 80% of patients received surgical resection, varying from 58% (Estonia) to 92% (Tarn) by registry, with Estonia, Amiens, Cracow and Mersey cancer registries less than 70%. Tables 3 and 4 show, for colon and rectum, respectively, the percentages of patients treated surgically, according to registry and age. The proportion treated surgically decreased with advancing age: from 85 to 73% for colon cancer, and from 85 to 70% for rectal cancer. This trend was evident for both cancer sites in most cancer registries. The proportion of treated patients aged over 74 ranged from 43% (Estonia) to 94% (Doubs) for colon cancer, and from 33% (Amiens) to 82% (Tarn, Rotterdam and Basel) for rectal cancer. Fairly large differences between registries, with respect to proportions receiving surgery, were also evident in the younger and in the middle age-group.
RESULTS
In addition to between-country variability, there was considerable variability within countries, which was particularly significant in France, Switzerland and the U.K. for both colon and rectal cancers (all ages, P < 0.005). No treatment differences in relation to sex were observed (not reported in Table) . Table 5 shows the age-standardised percentages of colon cancer patients who received chemotherapy, and rectal cancer patients given radiotherapy. Overall, only 4% of patients with ITest for homogeneity between countries: P < 0.001, between registries: P < 0.001. of cases that received a by-pass operation only. Note that, although this registry was unable to re-check its "therapy not known" cases (6% of total), 76% of these were histologically verified, suggesting that some of them had been resected. In contrast, the Cracow registry had a low proportion of surgical resections (60%) and the highest proportion of "therapy not known" (15% In the Finnish cancer registry, with a high proportion of surgical resections, this category may include a small number Cases notified to the registries by death certificate only were excluded from this analysis. These are patients who were not admitted to hospital, and for whom only palliative or no therapy was given; generally they remain at home for the terminal phase of their illness. Some cancer registries with a low proportion of DCOs actively sought clinical information on cases initially identified through death certificates, leading to the inclusion of unfavourable cases. The proportion of DC0 cases was highest in Poland and Thames (U.K.) and lowest in Switzerland and Varese, so it is unlikely that the proportion of DC0 cases substantially affected the proportion of treated patients. Furthermore, a recent study has provided [8] . Chemotherapy was, in fact, only given to l-12% of patients. (9) 43 (12) 37 (8) 18 (5) 14 (2) 22 (1) 23* (I) 27 (I) 22 (2) 12 (2) 34 ( both proportion of resected patients and survival probability correlate with this variable. However, quality of, and access to surgery, as well as access to endoscopy, may differ among countries and registry areas [9] , and these may also contribute to inter-country survival differences. Unfortunately, the staging information routinely available to registries is incomplete and insufficiently standardised, and more detailed comparisons are not possible.
Because cancer regisrries aim to record all the colorecral cancer cases in defined areas, the findings of this study are not influenced by the socio-demographic factors that often affect access to individual hospitals. These population-based results therefore probably reflect the real health care situation in the areas considered, although one small caveat would be that registries, particularly small ones, may be more likely to be present in areas where the local medical community has above-average interest in oncology, and this could positively influence the standard and availability of care in those areas.
In conclusion, the proportion of patients undergoing surgical resection for colorectal cancers varied widely across Europe in 1987. Since this variation correlates positively with the 5 year survival probability for these cancers (as reported in the EUROCARE study [I] ), it may be part of the explanation for the major differences in survival for these cancers among European populations. Factors such as diagnostic procedures and their relation to stage, which determine treatment and in particular whether a patient is resected, are currently being investigated by the EUROCARE group.
